Bookbot

Ernst Schering Research Foundation Workshop - 40: Recent Advances in Glucocorticoid Receptor Action

Maggiori informazioni sul libro

The long-term use of glucocorticoids is associated with several deleterious effects. Attempts to separate the beneficial from the adverse effects of these compounds have met with varying degrees of difficulty. The discovery of distinct modes of action of the glucocorticoid receptor, the protein that mediates glucocorticoid action has opened up many possibilities for improving glucocorticoid therapy. This book provides an in-depth overview of the molecular actions of the glucocorticoid receptor and discusses the chances of an imminent identification of selective glucocorticoid agonists. Such componds should fulfill all the criteria of a glucocorticoid but should lack the sideeffects so far linked with classical glucocorticoids.

Acquisto del libro

Ernst Schering Research Foundation Workshop - 40: Recent Advances in Glucocorticoid Receptor Action, A.C.B. Cato, H. Schacke, K. Asadullah

Lingua
Pubblicato
2002
product-detail.submit-box.info.binding
(Copertina rigida)
Ti avviseremo via email non appena lo rintracceremo.

Metodi di pagamento

Titolo
Ernst Schering Research Foundation Workshop - 40: Recent Advances in Glucocorticoid Receptor Action
Lingua
Inglese
Editore
Springer
Pubblicato
2002
Formato
Copertina rigida
Pagine
384
ISBN10
3540432299
ISBN13
9783540432296
Serie
Descrizione
The long-term use of glucocorticoids is associated with several deleterious effects. Attempts to separate the beneficial from the adverse effects of these compounds have met with varying degrees of difficulty. The discovery of distinct modes of action of the glucocorticoid receptor, the protein that mediates glucocorticoid action has opened up many possibilities for improving glucocorticoid therapy. This book provides an in-depth overview of the molecular actions of the glucocorticoid receptor and discusses the chances of an imminent identification of selective glucocorticoid agonists. Such componds should fulfill all the criteria of a glucocorticoid but should lack the sideeffects so far linked with classical glucocorticoids.